Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $44.29 Average Target Price from Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION) has earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $45.4286.

A number of equities research analysts have weighed in on SION shares. BTIG Research upped their target price on Sionna Therapeutics from $50.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday. Lifesci Capital began coverage on Sionna Therapeutics in a research note on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th.

Sionna Therapeutics Stock Down 15.3%

Sionna Therapeutics stock opened at $36.60 on Tuesday. The firm has a 50-day moving average price of $40.41 and a two-hundred day moving average price of $29.75. The firm has a market capitalization of $1.63 billion and a price-to-earnings ratio of -7.52. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Insider Transactions at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the sale, the director owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. This trade represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Peter A. Thompson sold 33,356 shares of the firm’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the sale, the director owned 3,561,655 shares in the company, valued at $158,671,730.25. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,501,826 shares of company stock valued at $56,263,103 over the last 90 days. Corporate insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its position in shares of Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after acquiring an additional 529 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics in the third quarter worth about $30,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics in the 2nd quarter valued at about $45,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Sionna Therapeutics by 13.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after acquiring an additional 4,489 shares during the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.